{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:34:24Z","timestamp":1783226064616,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107771","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:38:57Z","timestamp":1725622737000},"page":"107771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents"],"prefix":"10.1016","volume":"153","author":[{"given":"Bidyadhar","family":"Sethy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zih-Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iin","family":"Narwanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bau","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107771_b0005","doi-asserted-by":"crossref","unstructured":"D.A. Haber, E.R. Fearon, The promise of cancer genetics, Lancet 351 Suppl 2 (1998) SII1-8.","DOI":"10.1016\/S0140-6736(98)90326-9"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107771_b0010","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.14622","article-title":"Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review","volume":"40","author":"Kontomanolis","year":"2020","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted Cancer Therapy: The Next Generation of Cancer Treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr Drug Discov Technol"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","article-title":"Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107771_b0025","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/leu.2014.169","article-title":"The emerging roles of DOT1L in leukemia and normal development","volume":"28","author":"McLean","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107771_b0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/15592294.2019.1699991","article-title":"DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment","volume":"15","author":"Sarno","year":"2020","journal-title":"Epigenetics"},{"key":"10.1016\/j.bioorg.2024.107771_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.864612","article-title":"Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors","volume":"13","author":"Alexandrova","year":"2022","journal-title":"Front Genet"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107771_b0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","article-title":"Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase","volume":"112","author":"Min","year":"2003","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0050","doi-asserted-by":"crossref","first-page":"16862","DOI":"10.1038\/s41598-019-53239-6","article-title":"The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy","volume":"9","author":"Marcos-Villar","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107771_b0055","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bioorg.2024.107771_b0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-pathol-011811-132434","article-title":"The pathogenesis of mixed-lineage leukemia","volume":"7","author":"Muntean","year":"2012","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107771_b0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107771_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.exphem.2015.05.012","article-title":"Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond","volume":"43","author":"Chen","year":"2015","journal-title":"Exp Hematol"},{"issue":"25","key":"10.1016\/j.bioorg.2024.107771_b0075","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107771_b0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/14728221003623241","article-title":"Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development","volume":"14","author":"Barry","year":"2010","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107771_b0090","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bioorg.2024.107771_b0095","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.1021\/jm4007752","article-title":"A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L","volume":"56","author":"Anglin","year":"2013","journal-title":"J Med Chem"},{"issue":"42","key":"10.1016\/j.bioorg.2024.107771_b0100","doi-asserted-by":"crossref","first-page":"16746","DOI":"10.1021\/ja206312b","article-title":"Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies","volume":"133","author":"Yao","year":"2011","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107771_b0105","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1021\/acs.jmedchem.1c02228","article-title":"Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides","volume":"65","author":"Khirsariya","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107771_b0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bioorg.2018.07.022","article-title":"Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors","volume":"80","author":"Zhang","year":"2018","journal-title":"Bioorg Chem"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107771_b0115","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1021\/acs.jmedchem.2c00083","article-title":"Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9\/MLL-ENL","volume":"65","author":"Yuan","year":"2022","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107771_b0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acs.jcim.5b00738","article-title":"Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays","volume":"56","author":"Chen","year":"2016","journal-title":"J Chem Inf Model"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107771_b0125","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/acschembio.8b00933","article-title":"Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor","volume":"14","author":"Chen","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107771_b0130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1021\/acsmedchemlett.9b00452","article-title":"New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse","volume":"10","author":"Stauffer","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.107771_b0135","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ncomms2304","article-title":"Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors","volume":"3","author":"Yu","year":"2012","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.bioorg.2024.107771_b0140","first-page":"2780","article-title":"Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676)","volume":"128","author":"Shukla","year":"2016","journal-title":"Children with Relapsed or Refractory MLL-r Acute Leukemia, Blood"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107771_b0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/bdd.1889","article-title":"Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor","volume":"35","author":"Basavapathruni","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"24","key":"10.1016\/j.bioorg.2024.107771_b0150","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bioorg.2024.107771_b0155","doi-asserted-by":"crossref","first-page":"8066","DOI":"10.1021\/jm300917h","article-title":"Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L","volume":"55","author":"Anglin","year":"2012","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107771_b0160","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1021\/acs.jmedchem.9b02164","article-title":"Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300\/CBP","volume":"63","author":"Wu","year":"2020","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.bioorg.2024.107771_b0165","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.3390\/molecules26175300","article-title":"Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein","volume":"26","author":"Bon","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/biom8010011","article-title":"DOT1L and H3K79 Methylation in Transcription and Genomic Stability","volume":"8","author":"Wood","year":"2018","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107771_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112885","article-title":"Histone H3K79 methylation by DOT1L promotes Aurora B localization at centromeres in mitosis","volume":"42","author":"Yang","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.bioorg.2024.107771_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.926577","article-title":"Histone acetylation dynamics in repair of DNA double-strand breaks","volume":"13","author":"Aricthota","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107771_b0185","doi-asserted-by":"crossref","first-page":"2244696","DOI":"10.1080\/14756366.2023.2244696","article-title":"Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity","volume":"38","author":"Bao","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107771_b0190","article-title":"Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma","volume":"9","author":"Ma","year":"2021","journal-title":"In Silico, in Vitro, and SAR Studies, Front Chem"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682400676X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682400676X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:20:40Z","timestamp":1738203640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682400676X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S004520682400676X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107771","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107771"}}